INTRODUCTION
============

Late diagnosis contributes to relatively worse cancer survival rates in the UK,^[@b1],[@b2]^ with longer diagnostic intervals associated with higher mortality.^[@b3],[@b4]^ Although most of those with cancer present symptomatically to primary care,^[@b5],[@b6]^ diagnosis of cancer is not straightforward.^[@b7],[@b8]^ Patient-, doctor-, and system-related factors can all contribute to longer cancer diagnostic intervals.^[@b9]--[@b13]^ Concerns about potential diagnostic delays led to the implementation of urgent suspected cancer referral pathways,^[@b14],[@b15]^ based on referral criteria defined by the National Institute for Health and Care Excellence (NICE). These pathways enable rapid access to a specialist opinion or diagnostic test (2-week wait \[2WW\] in England) for patients with specified symptoms. Evidence shows time to diagnosis and start of treatment is shorter for patients referred urgently,^[@b16],[@b17]^ whereas longer diagnostic intervals are associated with more advanced cancers at diagnosis.^[@b18]^ The NICE suspected cancer referral guidelines were updated in June 2015,^[@b19]^ lowering the risk threshold for referral. Referrals have been increasing by approximately 10% year on year, with \>2 million referrals in England in 2018. As a result, more patients are being diagnosed with cancer following GP referrals, with significant reductions in those diagnosed via emergency routes.^[@b20]^ There is significant variation between practices in their use of urgent suspected cancer referrals,^[@b21]--[@b23]^ which has been a cause for concern.^[@b24]^ Use of urgent referrals varies by cancer site, with referral less likely for cancers characterised by non-specific presenting symptoms and patients belonging to low-cancer-incidence demographic groups.^[@b25]^

From financial year 2009/2010 a set of yearly suspected cancer referral metrics for every practice in England became available, produced by Public Health England (PHE).^[@b26]^ Previously published evidence that higher practice use of urgent referral is associated with lower cancer patient mortality^[@b27]^ was based on a single year (2009) cohort.

A more detailed analysis has been called for to understand variation in use of urgent referral pathways.^[@b14],[@b23],[@b28]^ This includes whether the association with cancer patient mortality can be replicated over a longer time period, is consistent across the main cancer types (colorectal, lung, breast, and prostate) --- which make up approximately half of all cancer cases, and the association with stage at diagnosis.^[@b27]^

METHOD
======

In this study, cancer registration data were extracted for all patients diagnosed with cancer (ICD-10 codes C00--C97, excluding non-melanoma skin cancer \[C44\]) between 2011 and 2015 in England from PHE's National Cancer Registration and Analysis Service (NCRAS).^[@b29]^ Demographic data included sex, deprivation, age at diagnosis, and vital status. For each tumour, data included diagnosis date, cancer type, stage at diagnosis, mortality, and the associated GP practice code.

###### 

How this fits in

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  There is considerable variation in use of urgent referral for suspected cancer between general practices. This study shows a significant association between higher practice use of urgent referral for suspected cancer and lower cancer patient mortality (2011--2015), for all cancers combined and for the most common types of cancer (colorectal, lung, breast, and prostate). A significant proportion of this reduction in mortality is likely due to earlier stage at diagnosis for all cancers, except colorectal. This study supports the observed increased use of urgent referral for suspected cancer in primary care following the updated National Institute for Health and Care Excellence guidelines.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

These tumours were linked to GP practice metrics on urgent referrals for suspected cancer, derived from the English national Cancer Waiting Times (CWT) database.^[@b30]^ These metrics were based on patients with a date of first hospital appointment or treatment recorded in financial years April 2011 to March 2016, relating to approximately 6.9 million urgent referrals for suspected cancer from \>9000 English general practices. Those with missing practice-level referral metrics were analysed separately.

Three practice-level referral metrics^[@b26]^ were used: practice referral ratio (RR) --- indirectly standardised number of urgent referrals for suspected cancer, standardised according to the general practice's registered list, and age--sex distributions (mean value 1);practice detection rate (DR) --- proportion of CWT-recorded cancers resulting from an urgent referral for suspected cancer (that is, the sensitivity of the selection of patients for urgent referral in the general practice); and,practice conversion rate (CR) --- proportion of urgent referrals for suspected cancer that result in a diagnosis of cancer (that is, the positive predictive value \[PPV\] for cancer among the patients selected for urgent referral).

Five-year aggregated practice referral metrics were used for all cancers, and metrics were separately calculated for each of the four most common types of cancer (colorectal, lung, breast, and prostate). Similar methods were used to those previously reported,^[@b27],[@b31]^ with referral metrics data analysed as categorical variables by converting rates into quintiles (that is, five groups of equal population).

Cox proportional hazards regression was used to quantify the hazard of death from any cause in relation to referral metric quintiles, including for the four main cancer types. All analyses were adjusted for the age, sex, and socioeconomic status of the individual patients. The main analysis used a 5-year time window of follow-up from diagnosis to death, ending at the earliest of 5 years or the study end date in 2017.

Logistic regression was used to calculate the odds of late-stage (III/IV) versus early-stage (I/II) cancer at diagnosis in relation to referral quintiles. A further Cox proportional hazards regression was undertaken, in which stage at diagnosis (I to IV and missing) was taken into account. This was used to determine how much of the observed changes in mortality could potentially be related to stage at diagnosis (see [Figure 1](#fig1){ref-type="fig"}, with stage as a potential mediator between referral and mortality).

![***Possible associations between practice use of urgent referral and mortality, in the presence of a mediator (stage).***](bjgpJun-2020-70-695-e389-OA-1){#fig1}

Stratified and sensitivity analyses were pursued to assess the consistency and internal validity of the findings, including a shared frailty random effects model^[@b32],[@b33]^ to accommodate the multilevel structure of data where groups of patients with cancer belong to the same general practice list. All analyses were carried out with Stata 13 and 14.

RESULTS
=======

Of 1 469 160 new cancer registrations between 2011 and 2015 ([Figure 2](#fig2){ref-type="fig"}), 57 registrations were excluded because of a negative duration of follow-up (that is, they were reported as having died before their cancer was registered). During follow-up 660 606 deaths occurred (45.0%) (for the increase in urgent referrals for suspected cancer from 2009/2010 to 2016/2017, and the impact on detection and conversion rates in England, see Supplementary Figure S1).

![***Flow diagram of study population with inclusions and exclusions.***](bjgpJun-2020-70-695-e389-OA-2){#fig2}

Cohort characteristics
----------------------

[Table 1](#table1){ref-type="table"} reports demographic and tumour-related characteristics of the 1 469 103 cancer registrations included.

###### 

Characteristics of the study cohort

  **Variable**                         **Colorectal**   **Lung**   **Breast**   **Prostate**   **Other**   **Total**                                                  
  ------------------------------------ ---------------- ---------- ------------ -------------- ----------- ----------- --------- ------- --------- ------ ----------- ------
  **Year of diagnosis**                                                                                                                                               
  2011                                 34 781           20.1       35 849       19.3           41 937      18.9        36 768    18.7    131 811   19.1   281 146     19.1
  2012                                 35 241           20.3       37 250       20.0           43 038      19.4        38 082    19.4    135 742   19.6   289 353     19.7
  2013                                 34 269           19.8       37 410       20.1           44 770      20.2        41 355    21.0    140 997   20.4   298 801     20.3
  2014                                 34 279           19.8       37 868       20.4           46 166      20.8        40 231    20.4    141 297   20.4   299 841     20.4
  2015                                 34 723           20.0       37 641       20.2           45 784      20.7        40 309    20.5    141 505   20.5   299 962     20.4
                                                                                                                                                                      
  **Male**                             96 306           55.6       100 512      54.0           0           0.0         196 745   100.0   356 394   51.6   749 957     51.0
                                                                                                                                                                      
  **Female**                           76 987           44.4       85 506       46.0           221 695     100.0       0         0.0     334 958   48.4   719 146     49.0
                                                                                                                                                                      
  **Age band in years at diagnosis**                                                                                                                                  
  0--9                                 17               0.0        11           0.0            0           0.0         6         0.0     5092      0.7    5126        0.3
  10--19                               382              0.2        20           0.0            15          0.0         0         0.0     4736      0.7    5153        0.4
  20--29                               955              0.6        168          0.1            1070        0.5         6         0.0     15 357    2.2    17 556      1.2
  30--39                               2475             1.4        603          0.3            8082        3.6         35        0.0     25 238    3.7    36 433      2.5
  40--49                               6533             3.8        4017         2.2            33 845      15.3        2108      1.1     50 157    7.3    96 660      6.6
  50--59                               18 881           10.9       17 466       9.4            47 260      21.3        20 139    10.2    92 720    13.4   196 466     13.4
  60--69                               41 841           24.1       49 054       26.4           56 719      25.6        66 511    33.8    160 391   23.2   374 516     25.5
  70--79                               52 402           30.2       63 508       34.1           39 089      17.6        70 260    35.7    178 541   25.8   403 800     27.5
  80--89                               41 661           24.0       43 782       23.5           28 181      12.7        32 241    16.4    131 084   19.0   276 949     18.9
  ≥90                                  8146             4.7        7389         4.0            7434        3.4         5439      2.8     28 036    4.1    56 444      3.8
                                                                                                                                                                      
  **Ethnicity**                                                                                                                                                       
  White                                151 041          87.2       162 955      87.6           185 967     83.9        163 013   82.9    588 007   85.1   1 250 983   85.2
  Mixed                                436              0.3        395          0.2            973         0.4         648       0.3     2542      0.4    4994        0.3
  Asian                                2634             1.5        2226         1.2            5788        2.6         2831      1.4     16 146    2.3    29 625      2.0
  Black                                2090             1.2        1499         0.8            3700        1.7         5493      2.8     9681      1.4    22 463      1.5
  Chinese                              374              0.2        333          0.2            580         0.3         232       0.1     1459      0.2    2978        0.2
  Other                                1445             0.8        1316         0.7            2312        1.0         1448      0.7     6788      1.0    13 309      0.9
  Unknown                              15 273           8.8        17 294       9.3            22 375      10.1        23 080    11.7    66 729    9.7    144 751     9.9
                                                                                                                                                                      
  **Deprivation quintile**                                                                                                                                            
  1 --- Least deprived                 39 133           22.6       27 661       14.9           52 523      23.7        50 180    25.5    147 216   21.3   316 713     21.6
  2                                    39 222           22.6       33 855       18.2           50 806      22.9        47 269    24.0    151 352   21.9   322 504     22.0
  3                                    36 421           21.0       37 795       20.3           46 244      20.9        40 889    20.8    143 742   20.8   305 091     20.8
  4                                    32 209           18.6       41 363       22.2           40 004      18.0        32 820    16.7    132 040   19.1   278 436     19.0
  5 --- Most deprived                  26 308           15.2       45 344       24.4           32 118      14.5        25 587    13.0    117 002   16.9   246 359     16.8
                                                                                                                                                                      
  **Stage at diagnosis**                                                                                                                                              
  I                                    23 543           13.6       24 724       13.3           82 528      37.2        52 736    26.8    133 428   19.3   316 959     21.6
  II                                   35 968           20.8       13 127       7.1            73 156      33.0        34 749    17.7    55 482    8.0    212 482     14.5
  III                                  39 418           22.7       34 234       18.4           17 429      7.9         31 140    15.8    59 427    8.6    181 648     12.4
  IV                                   36 214           20.9       87 066       46.8           11 119      5.0         31 960    16.2    108 842   15.7   275 201     18.7
  Not known                            38 150           22.0       26 867       14.4           37 463      16.9        46 160    23.5    334 173   48.3   482 813     32.9
                                                                                                                                                                      
  **2WW referral group**                                                                                                                                              
  2WW                                  55 641           32.1       55 806       30.0           98 517      44.4        88 507    45.0    219 732   31.8   518 203     35.3
  Not a 2WW                            76 961           44.4       75 999       40.9           87 754      39.6        60 232    30.6    244 595   35.4   545 541     37.1
  Tumour not in CWT database           40 691           23.5       54 213       29.1           35 424      16.0        48 006    24.4    227 025   32.8   405 359     27.6
                                                                                                                                                                      
  Total                                173 293          11.8       186 018      12.7           221 695     15.1        196 745   13.4    691 352   47.1   1 469 103   

2WW = two-week wait. CWT = Cancer Waiting Times.

The four most common types of cancer were identified. They were: colorectal (*n* = 173 293; 11.8%), lung (*n* = 186 018; 12.7%), breast (*n* = 221 695; 15.1%), and prostate (*n* = 196 745; 13.4%), together accounting for 52.9% of the cohort. One-third (32.9%) of the cohort had missing stage data, with variation by cancer type. Separate analysis was done of the 51 640 (3.5%) cancer registrations with missing 5-year GP referral data (see Supplementary Table S1 for details). Analysis of the cohort showed that approximately 1% of cancer patients changed practice within 4 months of referral, and approximately 2.5% changed practice within 4 months of diagnosis.

Distributions of referral metrics
---------------------------------

[Table 2](#table2){ref-type="table"} reports values for the three practice referral metrics. For all cancers combined, RR medians varied from 0.67 to 1.36, DR medians from 0.38 to 0.56, and CR medians from 0.06 to 0.13. Practices in the highest referral ratio quintile utilised the urgent referral pathway approximately twice as much as those in the lowest quintile.

###### 

Quintiles of practice referral metrics (RR/DR/CR) for all cancers combined and specific cancer type

  **Practice referral indices**   **Total (all cancers combined)**   **Colorectal**   **Lung**   **Breast**   **Prostate**                                                                                     
  ------------------------------- ---------------------------------- ---------------- ---------- ------------ -------------- ------ -------- -------- ------ -------- -------- ------ -------- -------- ------ ------
  **RR quintiles**                Q1                                 283 567          19.3       0.67         33 500         19.3   0.60     35 748   19.2   0.52     43 006   19.4   0.61     38 062   19.3   0.59
  Q2                              283 510                            19.3             0.86       33 529       19.3           0.82   35 790   19.2     0.77   42 924   19.4     0.86   38 037   19.3     0.83   
  Q3                              283 408                            19.3             1.00       33 476       19.3           0.99   35 708   19.2     0.98   42 965   19.4     1.02   38 042   19.3     1.00   
  Q4                              283 580                            19.3             1.14       33 505       19.3           1.16   35 755   19.2     1.25   42 955   19.4     1.18   38 057   19.3     1.18   
  Q5                              283 398                            19.3             1.36       33 479       19.3           1.45   35 736   19.2     1.81   42 961   19.4     1.44   38 035   19.3     1.49   
  Missing                         51 640                             3.5                         5804         3.3                   7281     3.9             6881     3.1             6512     3.3             
                                                                                                                                                                                                               
  **DR quintiles**                Q1                                 283 796          19.3       0.38         33 786         19.5   0.20     36 576   19.7   0.17     43 096   19.4   0.34     38 220   19.4   0.39
  Q2                              283 615                            19.3             0.44       36 006       20.8           0.31   34 949   18.8     0.32   43 866   19.8     0.42   38 112   19.4     0.52   
  Q3                              283 702                            19.3             0.48       34 597       20.0           0.38   35 821   19.3     0.40   42 038   19.0     0.48   37 774   19.2     0.59   
  Q4                              283 559                            19.3             0.51       30 019       17.3           0.43   35 669   19.2     0.47   43 041   19.4     0.54   38 620   19.6     0.67   
  Q5                              282 791                            19.3             0.56       33 058       19.1           0.52   35 697   19.2     0.57   42 762   19.3     0.63   37 443   19.0     0.76   
  Missing                         51 640                             3.5                         5827         3.4                   7306     3.9             6892     3.1             6576     3.3             
                                                                                                                                                                                                               
  **CR quintiles**                Q1                                 283 585          19.3       0.06         33 614         19.4   0.02     35 777   19.2   0.09     43 128   19.5   0.06     38 101   19.4   0.06
  Q2                              283 585                            19.3             0.08       33 416       19.3           0.04   35 797   19.2     0.17   43 178   19.5     0.08   37 993   19.3     0.09   
  Q3                              283 308                            19.3             0.09       33 518       19.3           0.05   35 669   19.2     0.22   42 669   19.3     0.09   38 800   19.7     0.11   
  Q4                              283 657                            19.3             0.10       33 520       19.3           0.06   36 086   19.4     0.27   42 871   19.3     0.11   37 334   19.0     0.14   
  Q5                              283 328                            19.3             0.13       33 476       19.3           0.08   35 382   19.0     0.33   42 965   19.4     0.15   38 003   19.3     0.18   
  Missing                         51 640                             3.5                         5749         3.3                   7307     3.9             6884     3.1             6514     3.3             

CR = conversion ratio. DR = detection ratio. RR = referral ratio.

Mortality and stage analysis
----------------------------

### All cancers

[Table 3](#table3){ref-type="table"} shows 5-year all-cause mortality, odds of late- versus early-stage cancer at diagnosis, and mortality taking stage into account, in relation to quintiles of practice referral metrics.

###### 

Analysis of mortality and stage for all cancers in relation to quintiles of referral metrics

  ----------------------------------------------------------------------- --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ -------- ---------- ----------
  **(a) 5-year HR-based (adjusted for age, sex, socioeconomic status)**                                                                                                                             
                                                                                                                                                                                                    
  **Standardised RR quintiles**                                           **HR**    **L CI**   **U CI**   **DR quintiles**   **HR**    **L CI**   **U CI**   **CR quintiles**   **HR**   **L CI**   **U CI**
                                                                                                                                                                                                    
  1                                                                       1.00      1          1.00       1                  1.00                                                                   
  2                                                                       0.98      0.98       0.99       2                  0.98      0.97       0.98       2                  1.02     1.02       1.03
  3                                                                       0.97      0.96       0.98       3                  0.97      0.96       0.98       3                  1.02     1.01       1.03
  4                                                                       0.97      0.96       0.98       4                  0.96      0.95       0.97       4                  1.00     1.00       1.01
  5                                                                       0.96      0.96       0.97       5                  0.95      0.94       0.95       5                  1.01     1.01       1.02
  χ^2^ (one df)                                                           106.4                           χ^2^ (one df)      187.9                           χ^2^ (one df)      0.03                
  *P* for trend                                                           \<0.001                         *P* for trend      \<0.001                         *P* for trend      0.872               
  ----------------------------------------------------------------------- --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ -------- ---------- ----------

  ------------------------------------------------------------------------------------------------------------ --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ --------- ---------- ----------
  **(b) Odds of stage III/IV versus I/II cancer at diagnosis (adjusted for age, sex, socioeconomic status)**                                                                                                                              
                                                                                                                                                                                                                                          
  **Standardised RR quintiles**                                                                                OR        **L CI**   **U CI**   **DR quintiles**   **OR**    **L CI**   **U CI**   **CR quintiles**   **OR**    **L CI**   **U CI**
                                                                                                                                                                                                                                          
  1                                                                                                            1.00      1          1.00       1                  1.00                                                                    
  2                                                                                                            0.99      0.98       1.00       2                  0.97      0.96       0.98       2                  0.99      0.98       1.01
  3                                                                                                            0.97      0.96       0.98       3                  0.98      0.96       0.99       3                  0.98      0.97       0.99
  4                                                                                                            0.97      0.95       0.98       4                  0.97      0.96       0.99       4                  0.97      0.96       0.98
  5                                                                                                            0.97      0.95       0.98       5                  0.96      0.94       0.97       5                  0.98      0.97       1.00
  χ^2^ (one df)                                                                                                38                              χ^2^ (one df)      26.1                            χ^2^ (one df)      14.7                 
  *P* for trend                                                                                                \<0.001                         *P* for trend      \<0.001                         *P* for trend      \<0.001              
  ------------------------------------------------------------------------------------------------------------ --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ --------- ---------- ----------

  ---------------------------------------------------------------------------------------- --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ --------- ---------- ----------
  **(c) 5-year HR (adjusted for age, sex, socioeconomic status) and adjusted for stage**                                                                                                                              
                                                                                                                                                                                                                      
  **Standardised RR quintiles**                                                            **HR**    **L CI**   **U CI**   **DR quintiles**   **HR**    **L CI**   **U CI**   **CR quintiles**   **HR**    **L CI**   **U CI**
                                                                                                                                                                                                                      
  1                                                                                        1.00      1          1.00       1                  1.00                                                                    
  2                                                                                        0.99      0.98       1.00       2                  0.99      0.98       1.00       2                  1.04      1.03       1.05
  3                                                                                        0.99      0.98       1.00       3                  0.98      0.98       0.99       3                  1.05      1.04       1.06
  4                                                                                        0.98      0.98       0.99       4                  0.97      0.97       0.98       4                  1.04      1.03       1.05
  5                                                                                        0.98      0.97       0.98       5                  0.97      0.96       0.97       5                  1.05      1.04       1.06
  χ^2^ (one df)                                                                            31.9                            χ^2^ (one df)      96.7                            χ^2^ (one df)      100.9                
  *P* for trend                                                                            \<0.001                         *P* for trend      \<0.001                         *P* for trend      \<0.001              
  ---------------------------------------------------------------------------------------- --------- ---------- ---------- ------------------ --------- ---------- ---------- ------------------ --------- ---------- ----------

CI = confidence intervals. CR = conversion ratio. df = degrees of freedom. DR = detection ratio. HR = hazard ratio. L = lower. OR = odds ratio. RR = referral ratio. U = upper.

Higher RR and DR quintiles were both significantly associated (*P*\<0.001) with lower hazard of death for all cancer patients ([Table 3a](#table3){ref-type="table"}), with four and five percentage point reductions in mortality, respectively. Moving from lowest to highest quintiles for RR and DR showed a consistent significant trend in the association with lower mortality. CR was not significantly associated with mortality (*P* = 0.872).

Higher practice referral (RR/DR/CR) quintiles were all significantly associated with lower odds of late-stage versus early-stage cancer at diagnosis (*P*\<0.001) ([Table 3b](#table3){ref-type="table"}). For the highest compared with lowest quintiles of RR and DR this equates to a two or three percentage point decrease in late-stage cancers at diagnosis.

After adjustment for stage at diagnosis, hazard ratios for the highest quintiles of RR and DR were attenuated ([Table 3c](#table3){ref-type="table"} compared with [Table 3a](#table3){ref-type="table"}), suggesting approximately half of the relative reductions in mortality for higher use of referral are potentially due to reductions in late-stage cancers at diagnosis. When stage was taken into account, higher CR quintiles were associated with a larger hazard of death (HR = 1.05; CI = 1.04 to 1.06) for highest CR quintile.

The patterns of association were consistent for sensitivity analyses, including 1-year mortality, and from a shared frailty random effects model accounting for clustering in GP practices.

### Main cancer subtypes

See Supplementary Tables S2 to S4 for a report of colorectal, lung, breast, and prostate cancer cohorts in relation to quintiles of their specific referral indices.

For the four most common cancer subtypes, similar significant associations were also found between higher RRs and lower hazard of death over 5 years (*P*-values of \<0.001, except for breast cancer \[*P* = 0.005\]).

Higher RRs were associated with lower odds of late- versus early-stage cancers at diagnosis (Supplementary Tables S2b to S5b) for all cancer types except for colorectal cancers.

When cancer stage was taken into account, hazard ratios for increasing RR were attenuated for all cancer types, except colorectal.

[Table 4](#table4){ref-type="table"} summarises the percentage point difference from lowest to highest quintile of referral metrics (RR/DR/CR) for all cancers combined and most common types of cancer in relation to (a) 5-year mortality; (b) odds of late- versus early-stage cancers at diagnosis; and (c) 5-year mortality, taking stage into account. This demonstrates that a higher practice RR is significantly associated with lower cancer patient mortality and reduced late-stage diagnoses. This was found for all cancers and the most common types, except for late stage diagnosis for colorectal cancer. DR, and particularly CR, demonstrated less consistent associations.

###### 

Percentage point difference between lowest (Q1) to highest (Q5) quintiles of referral metrics for all cancers and the most common types of cancer

  ------------------------------------------- --------------------------------- -------------------------------------- --------------------------------------
  **(a) 5-year mortality between Q1 to Q5**   **Percentage point difference**                                          
                                                                                                                       
                                              **RR**                            **DR**                                 **CR**
                                                                                                                       
  All cancers combined                        **--**4%                          −5%                                    1%[^a^](#tfn4){ref-type="table-fn"}
  Colorectal                                  −5%                               −4%                                    −6%
  Lung                                        −5%                               −2%[^a^](#tfn4){ref-type="table-fn"}   0%[^a^](#tfn4){ref-type="table-fn"}
  Breast                                      −4%                               3%[^a^](#tfn4){ref-type="table-fn"}    −2%[^a^](#tfn4){ref-type="table-fn"}
  Prostate                                    −12%                              −4%                                    −10%
  ------------------------------------------- --------------------------------- -------------------------------------- --------------------------------------

  -------------------------------------------------------------------------------- -------------------------------------- ------------------------------------- --------------------------------------
  **(b) Odds of late- versus early-stage cancers at diagnosis between Q1 to Q5**                                                                                
                                                                                                                                                                
                                                                                   **RR**                                 **DR**                                **CR**
                                                                                                                                                                
  All cancers combined                                                             −3%                                    −4%                                   −2%
  Colorectal                                                                       −1%[^a^](#tfn4){ref-type="table-fn"}   3%[^a^](#tfn4){ref-type="table-fn"}   −3%[^a^](#tfn4){ref-type="table-fn"}
  Lung                                                                             −8%                                    2%[^a^](#tfn4){ref-type="table-fn"}   0%[^a^](#tfn4){ref-type="table-fn"}
  Breast                                                                           −5%                                    14%                                   0%[^a^](#tfn4){ref-type="table-fn"}
  Prostate                                                                         −9%                                    8%                                    −9%
  -------------------------------------------------------------------------------- -------------------------------------- ------------------------------------- --------------------------------------

  --------------------------------------------------------------------- ------------------------------------- -------------------------------------- --------------------------------------
  **(c) 5-year mortality between Q1 to Q5 taking stage into account**                                                                                
                                                                                                                                                     
                                                                        **RR**                                **DR**                                 **CR**
                                                                                                                                                     
  All cancers combined                                                  −2%                                   −3%                                    5%
  Colorectal                                                            −6%                                   −4%                                    −2%[^a^](#tfn4){ref-type="table-fn"}
  Lung                                                                  −3%                                   −2%[^a^](#tfn4){ref-type="table-fn"}   3%
  Breast                                                                0%[^a^](#tfn4){ref-type="table-fn"}   3%[^a^](#tfn4){ref-type="table-fn"}    3%[^a^](#tfn4){ref-type="table-fn"}
  Prostate                                                              −8%                                   −4%                                    −4%
  --------------------------------------------------------------------- ------------------------------------- -------------------------------------- --------------------------------------

No statistically significant trend over quintiles. CR = conversion ratio. DR = detection ratio. RR = referral ratio.

Missing GP referral data
------------------------

Of the total number of cases, 51 640 (3.5%) did not have GP referral data available (see Supplementary Table 1b for characteristics). Although those cohorts with missing GP referral data were of similar age distribution to the total cohort, they had lower white population (75.4% white in the missing referral data group versus 89.9% in total cohort) and showed higher rates of social deprivation (21.3% from the most deprived quintile in the missing referral data group versus 16.8% in the overall cohort). The missing referral data group also had lower rates of cancer diagnosis following urgent referral (28.2% versus 35.3%), and higher rates of unknown stage at diagnosis (40.6% versus 32.9%) compared with the overall cohort. Of the total, 44 852 cases (86.9%) had a registered practice code but the practice did not have a full 5 years of referral data, primarily due to practice changes (for example, closure) or small list size (\<1000). Cases numbering 6795 (13.2%) were without practice code, including those who were unregistered with a GP practice and those for whom NCRAS could not determine the registered practice.

Those with missing GP referral data were found to have an overall higher hazard of death over 5 years compared with those with practice referral data (HR = 1.15; CI = 1.14 to 1.17; *P*\<0.001).

DISCUSSION
==========

Summary
-------

This analysis of \>1.4 million patients diagnosed with cancer in England between 2011 and 2015 shows that a greater propensity to use referrals for suspected cancer was associated with lower mortality for all cancers combined and for the most common types of cancer. Significant reductions in late-stage cancers at diagnosis were found for patients from practices with higher RRs, including for the most common types of cancer, except for colorectal cancer, where there was not a significant association.

Overall, the accuracy in case selection for urgent referral (CR) was not significantly associated with mortality or stage at diagnosis. But when stage was taken into account there was an increase in mortality with the highest CR quintiles.

A large proportion (one-third to half) of the observed reduction in mortality with higher use of urgent referral is likely to be explained by earlier stage at diagnosis --- except for colorectal cancer, where lead time or other confounders may play a more important role*.*

Cancer patients with missing GP referral data (due to their practice not having 5-years' referral data or not having an identifiable practice) showed significantly higher mortality.

This study has demonstrated that lower mortality and a reduction in late-stage cancers at diagnosis are associated with higher referral use. This supports the hypothesis that increased primary care use of urgent suspected cancer referrals and associated diagnostic testing may reduce late-stage diagnoses and mortality of patients with cancer.^[@b34],[@b35]^

Strengths and limitations
-------------------------

The analysis was based on the complete national population of England, using all CWT records and population-based cancer registrations for 2011--2015. This reduces biases that can arise from the waiting times paradox,^[@b16],[@b36]^ where patients with short and long times to treatment are compared.^[@b37]^ Also, direct comparison of urgently referred and non-referred patients is subject to selection bias and confounding by indication.^[@b38],[@b39]^

As effects on mortality were estimated by time to event (death), lead time may contribute to the observed effect. Lead-time research has been focused primarily on screening,^[@b40],[@b41]^ and in particular breast^[@b42],[@b43]^ and prostate cancers,^[@b44]^ with relatively little mention in early symptomatic diagnosis literature.^[@b27],[@b45],[@b46]^

The most likely causes of case-mix variation between the general practices were adjusted for.^[@b25],[@b47],[@b48]^ Similar associations were found in sensitivity analyses accounting for cancer patient clustering at a practice level^[@b33]^ and for both 1-year and 5-year mortality, suggesting robust results. However, as in any observational study, the possibility of confounding remains.^[@b38],[@b49]^

With \>4% of patients changing practice in the study cohort, this suggests that the registered GP practice referral metrics give an accurate indication of referral patterns for the majority of patients.

At a practice level, urgent referral metrics for a single year can be based on relatively small numbers of referrals and cancer cases, meaning they exhibit year-on-year random variation,^[@b28]^ with differences in case-mix^[@b50]^ and in referral selection accuracy and thresholds.^[@b51]^ By using 5-year aggregated metrics, year-on-year random variation is reduced (although not completely excluded) and reliability should be improved. Even for 1-year metrics, process measures such as referral rate were shown to demonstrate acceptable reliability,^[@b28]^ although longer time-intervals are likely required for cancer-specific referral metrics and outcome measures such as conversion and detection rates.

Outcome measures included all-cause mortality and late versus early stage at diagnosis, and then mortality analysis taking stage into account (I to IV and missing) (see [Table 4a to 4c](#table4){ref-type="table"} and Supplementary Tables S2 to S5 for details) to understand the potential impact of stage on observed mortality ([Figure 1](#fig1){ref-type="fig"}). Although approximately one-third of the cohort having missing stage means the subsequent mortality analysis is potentially less robust, over time stage is increasingly better recorded within cancer registration data.

Comparison with existing literature
-----------------------------------

This study confirms the association between higher overall practice utilisation of suspected cancer referral pathways and lower patient mortality for all cancers,^[@b27]^ previously found for a single-year (2009) cohort study.^[@b23]^ It is also consistent with a previous study that showed an association between lower levels of referral from English general practices for gastroscopy (2006--2008) and worse patient outcomes for oesophageal-gastric cancers.^[@b52]^

In a study using data from 2012 on referral and cancer stage,^[@b53]^ higher use of urgent referral of patients with suspected cancer was associated with a smaller proportion of patients having advanced cancer. To the authors' knowledge, this study for the first time included mortality, stage at diagnosis, and the impact of stage on mortality for all cancers and the most common types of cancer.

As noted, there have been studies investigating the reliability of these routinely collected practice measures^[@b28],[@b50],[@b51]^ and around practice and GP characteristics associated with their use.^[@b47],[@b54]^

Higher practice CRs were associated with higher mortality when stage was taken into account for all cancers, suggesting worse outcomes. This could be due to a high threshold for referral by some GPs, with research showing an association between CRs and individual GP decision making.^[@b55]^

Although this study focused on primary care and GP referrals for suspected cancer, there is clearly potential variation once patients are referred, including in the clinical practice of individual specialists, treatments offered, and in the wider healthcare system^[@b31]^ that are important to consider.^[@b56]^

Implications for research and practice
--------------------------------------

The significant reduction in mortality between lower and higher use of urgent referral of between four and five percentage points approaches the magnitude of known and important differences between England and comparable countries.^[@b57],[@b58]^ The number of referrals did increase over the period of the study and have continued to do so, with an associated increase in the number of cancer patients diagnosed following GP referral and a decrease in the proportion of cancer patients diagnosed via emergency routes, in whom there are worse outcomes,^[@b39]^ from 25% to 20%.^[@b20]^

Further investigations are warranted into the different scale of impact on mortality and stage at diagnosis for other specific cancer-site referral pathways, including the effect of lead time^[@b41],[@b46]^ in symptomatic diagnosis --- which is under-researched --- and other potential mediators. In particular, there is a need to understand reasons for the observed lack of mortality reduction when stage is taken into account for colorectal cancer patients. This could include the impact of colorectal screening programmes, or, more recently, the use of Faecal Immunochemical Testing (FIT) in both screening and symptomatic presentation. Further work is needed to understand the factors associated with variation in referral including at individual GP,^[@b55]^ practice,^[@b47]^ and wider healthcare organisation levels.^[@b56]^

Although this study focuses on symptomatic urgent referral pathways for all cancers combined and the four most common cancer types, cancers characterised by lower-risk non-specific presenting symptoms (for example, multiple myeloma or pancreas) are likely to have multiple GP consultations prior to referral^[@b59]^ and pose diagnostic challenges.^[@b25]^ Further development and implementation of evidence-based clinical decision tools,^[@b34],[@b60]^ including addressing issues around clinician cognitive error^[@b61],[@b62]^ and the potential of future novel biomarkers^[@b60],[@b63]^ are needed to aid earlier cancer detection --- especially for difficult-to-diagnose cancer types.

This research adds to evidence supporting the policy of lowering referral thresholds from primary care and subsequent increased use of suspected cancer referral pathways.^[@b19]^ Recommendations supporting higher 2WW referral rates need to be tempered by an understanding of the healthcare system. Also, the health economic implications need to be further explored,^[@b34]^ especially given finite staff and resources,^[@b64]^ and the risks of overdiagnosis.^[@b64],[@b65]^ With referrals in England (and other countries) increasing year on year, additional risk assessment and triage testing in primary care before referral for certain cancers, such as colorectal,^[@b60],[@b63]^ may be indicated.

This study uses data provided by patients and collected by the NHS as part of its care and support. Data for this study are based on patient-level information collected by the NHS, as part of the care and support of cancer patients. The data are collated, maintained, and quality assured by the NCRAS, which is part of PHE. The authors would like to thank their patient and public involvement steering group, which provided input to this programme of research (NIHR-funded DRF).
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